These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 7898099)

  • 1. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
    Fleckenstein-Grün G; Thimm F; Czirfuzs A; Matyas S; Frey M
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S75-84. PubMed ID: 7898099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists.
    Fleckenstein-Grün G; Frey M; Thimm F; Luley C; Czirfusz A; Fleckenstein A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 6():S1-9. PubMed ID: 1725909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of calcium in arteriosclerosis--experimental evaluation of antiarteriosclerotic potencies of Ca antagonists. Study Group for Calcium Antagonism.
    Fleckenstein-Grün G; Thimm F; Frey M; Czirfusz A
    Basic Res Cardiol; 1994; 89 Suppl 1():145-59. PubMed ID: 7945169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats.
    Fleckenstein-Grün G; Thimm F; Frey M; Matyas S
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):207-13. PubMed ID: 7475044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Possibilities in the future application of calcium antagonists. Is the prevention of blood vessel calcinosis possible?].
    Fleckenstein A; Frey M; Fleckenstein-Grün G
    Fortschr Med; 1984 Jul; 102(27-28):713-7. PubMed ID: 6479813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of various calcium antagonists against experimental arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Fleckenstein A
    J Hum Hypertens; 1992 Dec; 6 Suppl 1():S13-8. PubMed ID: 1293304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor effects of diltiazem, nicardipine, nifedipine and verapamil on the norepinephrine-induced contractions of the canine saphenous vein in calcium-free medium.
    Saïag B; Milon D; Bentue-Ferrer D; Allain H; Rault B; Van den Driessche J
    Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):255-69. PubMed ID: 8008975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part I. Preventive effects of calcium antagonists in animal experiments.
    Frey M; Just H
    Basic Res Cardiol; 1994; 89 Suppl 1():161-76. PubMed ID: 7945170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium--a neglected key factor in arteriosclerosis. The pathogenic role of arterial calcium overload and its prevention by calcium antagonists.
    Fleckenstein-Grün G; Fleckenstein A
    Ann Med; 1991; 23(5):589-99. PubMed ID: 1756029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers and atherosclerosis.
    Sowers JR
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):3-9. PubMed ID: 2220798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcification of the arterial wall in the aging process. Electron microscopic and biochemical studies of a model of vitamin D3 overdose].
    Seydewitz V; Staubesand J
    Aktuelle Gerontol; 1983 May; 13(3):115-8. PubMed ID: 6135358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. History of calcium antagonists.
    Fleckenstein A
    Circ Res; 1983 Feb; 52(2 Pt 2):I3-16. PubMed ID: 6339106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.
    Opie LH
    Q J Med; 1984; 53(209):1-16. PubMed ID: 6324268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on the mechanisms of the antiatherogenic effect of Ca-antagonists].
    Birou S
    Igaku Kenkyu; 1988 Apr; 58(2):77-84. PubMed ID: 3245408
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of magnesium on calcium responses to vasopressin in vascular smooth muscle cells of spontaneously hypertensive rats.
    Touyz RM; Laurant P; Schiffrin EL
    J Pharmacol Exp Ther; 1998 Mar; 284(3):998-1005. PubMed ID: 9495860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium overload--an important cellular mechanism in hypertension and arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Hofgärtner W; Fleckenstein A
    Drugs; 1992; 44 Suppl 1():23-30. PubMed ID: 1283581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension: calcium-blocking agents in treatment.
    Ambrose JE
    J Am Osteopath Assoc; 1984 Jan; 83(5):353-60. PubMed ID: 6321407
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium-channel blockers and systemic hypertension.
    Frishman WH; Charlap S; Ocken S; Spivack C
    J Clin Hypertens; 1985 Jun; 1(2):107-22. PubMed ID: 3915318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of two calcium channel blockers--nifedipine and diltiazem--on atherogenesis in hypercholesterolemic hamster.
    Raicu M; Pojoga L; Simionescu N; Simionescu M
    J Submicrosc Cytol Pathol; 1996 Apr; 28(2):265-75. PubMed ID: 8964051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiatherosclerotic effects of calcium antagonists. Study in human aortic cell culture.
    Orekhov AN; Baldenkov GN; Tertov VV; Ruda MYa ; Khashimov KA; Kudryashov SA; Ryong LH; Kozlov SG; Lyakishev AA; Tkachuk VA
    Herz; 1990 Apr; 15(2):139-45. PubMed ID: 1971612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.